EMA and European Chemicals Agency Strengthen Collaboration - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

EMA and European Chemicals Agency Strengthen Collaboration

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 6

The European Medicines Agency (EMA) and the European Chemicals Agency (ECHA) have entered into an agreement to strengthen the scientific dialogue between the two organizations through sharing expertise and scientific data between their scientific committees, working groups, and panels on matters of common interest.

The working agreement, signed by EMA Executive Director Guido Rasi and ECHA Executive Director Geert Dancet, outlines activities to ensure the best use of available resources and ensure coherence in scientific opinions. The organizations agree to exchange information regarding evaluation and authorization/restriction of chemicals, as relevant for the activities of EMA; share information concerning risk management through classification, labeling, and packaging of substances; cooperate on toxicological assessments by predictive methods and new methodologies; cooperate on biocides; exchange information on environmental risk assessment for both human and veterinary medicinal products and ecotoxicology; and participate in meetings and joint projects.

Source: European Medicines Agency


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here